Corporate Magazine 2012 - Boehringer Ingelheim

products for industrial customers cost-effectively and reliablyto high quality standards at all times.Boehringer Ingelheim undertook several risk and compliancemanagement initiatives in the 2012 financialyear. We are constantly working to improve our processesand to reduce the risks associated with our business. AQuality Risk Management (QRM) system was developedin 2012. In addition to a comprehensive risk analysis ofthe sites, specific processes such as the manufacturing orpacking process are assessed via QRM, thus ensuringtheir quality.The launch of new products for respiratory diseases andincreased sales of established products are leading tohigher demand for Boehringer Ingelheim’s respimat®Soft Mist Inhaler. The company therefore decided in2012 to increase capacity in Dortmund and Ingelheim to44 million packaging units by 2015 with a total investmentof EUR 163 million. The inhalation system is manufacturedby Boehringer Ingelheim microParts GmbH inDortmund and filled with the corresponding pharmaceuticalactive ingredients at the Ingelheim site for globaldistribution. Another example of the strengtheningof our production network is the investment project totallingjust under EUR 10 million at our site in Athens,Greece. At this ESP site, production and packaging capacityis being expanded to enable future production ofproducts in our anti-diabetes product range, for examplejentadueto®.BiopharmaceuticalsIn addition to the manufacture of proprietary products(actilyse®, metalyse®, imukin® and beromun®), thebiopharmaceutical production arm of Boehringer Ingelheimat the sites in the USA (Fremont), Germany (Biberach)and Austria (Vienna) is a globally respected contractmanufacturer for industrial customers. The companycovers the entire biopharmaceutical process chain fromgenetic development of the cell to manufacturing andright through to market launch.In the 2012 financial year, Boehringer Ingelheim enteredinto a strategic production agreement with the biotechnologycompany Molecular Partners AG to support theDARPin® production pipeline, which constitutes a newclass of biological active ingredients and which MolecularPartners AG specialises in researching, developing andmarketing. Furthermore, Boehringer Ingelheim concludeda production agreement with the biopharmaceutical companyApexigen, Inc. for the manufacture of APX005. Thisactive ingredient is a human monoclonal antibody and astrong CD40 agonist for cancer treatment. BoehringerIngelheim signed an agreement with the French companyServier S.A.S. and its partner XOMA Corporation on thecontract manufacturing of gevokizumab, which is currentlyin clinical phase III and is to be produced in Biberach infuture. In November 2012, Boehringer Ingelheim acquireda technology licence from BaroFold, Inc. that will be usefulin the development of biopharmaceutical productionprocesses.Animal HealthIn the field of animal health, Boehringer Ingelheimgained a European production site with approximately100 employees in 2012 through the acquisition of a vaccinefactory in the Netherlands (Weesp). In conjunctionwith the European Research Centre in Hanover, this hasput us in a position for further growth in Europe. A jointventure for construction of a production facility for animalvaccines was concluded in China as well. With totalinvestment of more than EUR 55.5 million, the plant willbe built in Taizhou China Medical City, a high-tech parkfor the pharmaceutical industry, and will manufacturevaccines for pigs and poultry for China and other Asianmarkets. This investment emphasises our long-termcommitment in China.Environmental and employee protectionThe observance of social and ecological concerns hasbeen firmly anchored within Boehringer Ingelheim’scorporate philosophy for many years and is of centralimportance in terms of our long-term development as acompany. This importance is reflected in our missionstatement, in which the protection of our employees, our28Boehringer Ingelheim annual report 2012